In Depth 30 Oct 2024
Spatial Transcriptomics: A window into disease
The emerging spatial transcriptomics field is letting researchers map out gene expression in tumor and brain samples. How could this change the way we treat disease?
About
Reporter for Labiotech. I hail from the UK. I was born in Bristol, studied Neuroscience in the University of Bristol, and trained mice in Eisai, Hertfordshire, for one year. I then tickled locusts for my Ph.D. at the University of Leicester, before eventually ending up here!
Out of the office, I travel, play video games and board games, drink beer and play the piano.
Articles by Jonathan Smith
Best in Biotech 15 May 2023
The six most advanced microbiome players aiming for the gut
After decades of research, gut microbiome therapies are beginning to reach the market. Here are six of the companies harnessing the power of the microbiome to develop treatments derived from the gut. Over the years, gastrointestinal research has increasingly focused on the role of the microbe communities residing in our gut, known collectively as the […]
In Depth 6 Mar 2023
The biggest private biotech investments in February 2023
The companies Aera Therapeutics, Hemab and Loam Bio bagged the biggest biotech investments in February 2023. Around the world, gene therapy, manufacturing and biomaterials attracted the most investor interest. Private biotech fundraising in February 2023 lacked the massive funding rounds seen in January, from the likes of Asimov and BioRay Pharmaceuticals. However, there was still […]
In Depth 6 Feb 2023
The biggest private biotech investments in January 2023
The companies Asimov, BioRay Pharmaceuticals and Colossal Biosciences bagged the biggest biotech investments in January 2023. Around the world, synthetic biology players and firms developing treatments for hormonal disorders attracted the biggest funding rounds. 2023 began with a bang in terms of biotech funding, and there are signs of stabilization in biotech stocks after two […]
Best in Biotech 12 Jan 2023
The biggest biotech trends that will shape 2023
2023 has begun at full throttle. We have collected seven major biotech trends that industry experts are keeping an eye on over the next 12 months. Just like that, another year has begun. 2023 has already launched with announcements of big pharma acquisitions and the approval of Eisai and Biogen’s Alzheimer’s drug lecanemab by the […]
In Depth 9 Jan 2023
The biggest private biotech investments in December 2022
The companies Apogee Therapeutics, Pulmocide and Qitan Technology bagged the biggest biotech investments in December 2022. Around the world, immunology and manufacturing players attracted the biggest funding rounds. We’ve hit 2023 and a lot of biotech fundraising took place in the final month of 2022. We’ve gathered the biggest biotech investments that went to private […]
ADVERTISEMENT
ADVERTISEMENT
In Depth 5 Jan 2023
Navignostics maps tumor proteomes to improve precision oncology
New cancer drugs are entering the market every year, but it’s hard to know which patients they benefit the most. The Swiss firm Navignostics is making spatial maps of the tumor’s proteome to identify the right treatment for the patient and boost precision oncology approaches. A wide range of technologies is being deployed in the […]
In Depth 22 Dec 2022
10 biotech companies to watch in 2023
2022 is coming to an end. Here is a list of biotech companies from around the world that we are keeping in our sights in 2023. The year 2022 has seen a lot of uncertainty in biotech markets, resulting in tumbling or volatile stocks. A high number of biotech companies are even trading with market […]
In Depth 20 Dec 2022
Ebvallo approval ushers in off-the-shelf T-cell immunotherapies
Patient-derived CAR-T immunotherapies have dominated the cancer immunotherapy space over the last decade. The EU approval of Atara Biotherapeutics’ Ebvallo marks the first immunotherapy based on T cells sourced from healthy donors. Since the approvals of Kymriah and Yescarta in 2017, CAR-T immunotherapies have changed the way we treat rare forms of blood cancer. In […]
Startup Scout 19 Dec 2022
Green Bioactives grows medicines in plant cells
Though plants may hold the key to new, effective medicines, sourcing these compounds sustainably is difficult. Green Bioactives devises eco-friendly ways to produce plant-derived drugs via plant cell cultures. For decades, the pharmaceutical industry has designed synthetic small molecule drugs and manufactured them via chemical synthesis. While this approach provides an easy way to supply […]
In Depth 15 Dec 2022
To avoid stagnation, the EU must refine its ATMP regulation
Over the decades, the EU has spearheaded the adoption of advanced therapy medicinal products (ATMPs) such as cell and gene therapies. However, changes are needed to ATMP regulations to keep Europe competitive with the rest of the world. The EU has a rich resource base in terms of biotech innovation. Over the last decades, this […]
Interview 14 Dec 2022
Sibylla Biotech: how physicists met biologists to discover new drugs
Discovering new drugs remains an inefficient, trial and error-based process. The founding team behind the Italian startup Sibylla Biotech explain how their interdisciplinary approach can speed up drug discovery in the protein degradation space. Protein degradation is a hot field in the biotech industry, with many pharmaceutical companies forging lucrative deals with protein degradation players. […]
ADVERTISEMENT
